By Inteledoc Expert Team | 10 min read | Dr. Naveen Satija, MBBS, FIAGES, DNB (Surgery)
Wegovy has become one of the most talked-about medicines in the world. Headlines across India have called it a breakthrough. Social media is full of beforeand-after stories. And search volumes for “Wegovy India” and “Wegovy price India” have exploded — which tells you that thousands of Indians are actively looking for access to this treatment. This blog gives you the honest, complete picture: what Wegovy is, whether it is actually available in India, what it costs, who it is genuinely right for, and what to do if you want to explore it safely.
What Is Wegovy? The Plain English Version
Wegovy is a brand name for semaglutide — a medicine that mimics a natural hormone your gut produces after eating, called GLP-1 (Glucagon-Like Peptide 1). This hormone sends a signal to your brain that says: you are full, slow down, stop eating. In people who struggle with weight, this signal is often too weak or too short-lived. Wegovy restores and strengthens it — reducing hunger, improving fullness, stabilising blood sugar, and helping the body shift from fat-storage mode to fat-burning mode.
Wegovy is specifically the higher-dose formulation of semaglutide — dosed at 2.4mg weekly — approved specifically for weight management rather than diabetes. Its sister medicine, Ozempic, contains the same active ingredient at a lower dose and is approved for type 2 diabetes. Both belong to the same GLP-1 class of medicines that have transformed the treatment of obesity globally over the last five years.
✗ COMMON MISCONCEPTION
Wegovy is just a shortcut for people who do not want to diet. Anyone can take it and lose weight without making any lifestyle changes.
Clinical trials — specifically the STEP programme — showed average weight loss of 14.9% of body weight over 68 weeks in patients on semaglutide 2.4mg combined with lifestyle support. The lifestyle component matters. Patients who used Wegovy without dietary and behavioural support consistently achieved lower results than those who combined the medicine with a proper programme. The medicine opens a biological window — the programme determines what you do inside it.
Is Wegovy Available in India in 2026?
This is the question most people are actually searching for. The honest answer: Wegovy (semaglutide 2.4mg, the specific Wegovy formulation) is not yet formally launched in India as of 2026. However, this does not mean that semaglutide is inaccessible to Indian patients under medical supervision.
Semaglutide in other formulations — including Ozempic (0.5mg and 1mg) and higher-dose semaglutide available through specialist prescription — is available in India and is used clinically for weight management by doctors specialising in obesity medicine, including at Inteledoc. The specific branded Wegovy product approval for India is anticipated, but physicians can currently access appropriate semaglutide doses for weight management through existing channels under prescription.
Additionally, tirzepatide — a newer dual GIP/GLP-1 medicine sold as Mounjaro globally, and showing even stronger weight loss results in trials — has also been prescribed by doctors in India for appropriate patients.
✓ THE CRITICAL POINT ON ACCESS
Semaglutide and related medicines require a valid prescription from a licensed doctor in India. Purchasing these medicines from unregulated online sources — without prescription, medical screening, or supervision — is both legally questionable and genuinely dangerous. Products sold start with a qualified doctor consultation. through informal channels may be counterfeit, incorrectly stored, or improperly dosed. Always
Wegovy Price India — What Does Semaglutide Actually Cost?
The cost question is the one that determines access for most people — and the honest answer is that pricing varies significantly based on the specific formulation, the dose, and the programme structure around it. Here is a realistic breakdown for Indian patients as of 2026.
The medicine itself — semaglutide at doses appropriate for weight management — costs approximately ₹8,000 to ₹20,000 per month depending on dose, formulation, and pharmacy. Tirzepatide, where available, is at the higher end of this range or above. These are medication costs alone, separate from consultation and programme fees.
A complete doctor-supervised GLP-1 weight loss programme — which includes the medical consultation, metabolic assessment, dietary support, and ongoing monitoring that makes the medicine both safe and effective — adds to this cost but is non-negotiable for responsible use. At Inteledoc, programme plans start from ₹1,500 per month , with the medicine discussed and prescribed separately based on clinical indication.
It is also worth noting that the cost of an effective medical programme compares favourably to the cumulative cost of years of ineffective commercial diets, gym memberships, and supplements — particularly when the medical programme actually produces lasting results.
consultation
Who Is Semaglutide / Wegovy Right For?
A GLP-1 medicine like semaglutide is clinically indicated for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, high blood pressure, elevated cholesterol, or obstructive sleep apnoea. For South Asian populations — including Indians — doctors frequently apply these thresholds at lower BMI values, given the well-documented tendency for metabolic complications to occur at lower body weights in this population.
Beyond these criteria, semaglutide is most appropriately used by people who have made genuine, sustained efforts through diet and lifestyle without achieving adequate results. It is a clinical intervention for a biological problem — not a first-line response to wanting to lose a few kilos before a wedding.
Contraindications include: personal or family history of medullary thyroid cancer or MEN2 syndrome, active pancreatitis, and pregnancy or planned pregnancy. A thorough pretreatment medical assessment identifies these contraindications — another reason why no prescription should ever be issued without it. See how Inteledoc’s doctor-supervised assessment process works here.
What a Proper Semaglutide Programme in India Looks Like
1. Comprehensive medical consultation.
Full health history, current medications, existing conditions, previous weight loss attempts, and clinical goals reviewed by a qualified doctor before any prescription.
2. Metabolic profiling.
Blood panel covering thyroid function, fasting insulin and glucose, lipid profile, liver function, and key nutritional markers — identifying the specific biological factors behind your weight difficulty.
3. Careful dose titration.
Starting at 0.25mg weekly and increasing gradually based on tolerance and response. Rushing this process is the primary cause of avoidable side effects.
4. Personalised dietary support.
A diet plan built around your metabolic profile and Indian food culture — not a generic template. Adequate protein, appropriate carbohydrate management, and culturally sustainable meal structure.
5. Regular clinical monitoring.
Check-ins every two to four weeks assessing weight, side effects, blood markers, and progress. Programme adjusted continuously based on real results.
Frequently Asked Questions
Both contain semaglutide, but at different doses and for different indications. Ozempic (0.5mg and 1mg) is approved for type 2 diabetes management. Wegovy (2.4mg) is approved specifically for weight management in adults with obesity or overweight with a health condition. In practice, doctors in India manage weight loss with appropriate semaglutide doses based on clinical indication, using what is currently available and approved.
Most patients notice appetite changes within two to four weeks of starting treatment. Meaningful weight loss is typically visible by weeks eight to twelve. Average weight loss in clinical trials was approximately 15% of body weight over 68 weeks — roughly one to two kilos per month in a well-managed programme.
The most common side effects are mild to moderate nausea, reduced appetite, and occasional fatigue — occurring mainly in the first two to six weeks and directly related to dose escalation speed. Gradual titration managed by a doctor minimises these significantly. Serious side effects are rare and are screened for before treatment begins.
Yes — Inteledoc offers online doctor consultations from anywhere in India, through which semaglutide can be assessed, prescribed, and monitored where clinically appropriate. The prescription requires a proper medical assessment, not just a form submission. Book your online consultation here.
Research shows that patients who stop semaglutide without having built sustainable dietary habits tend to regain a significant portion of lost weight over the following year. Patients who use the treatment period to establish lasting lifestyle changes maintain results much better. This is why Inteledoc’s programme focuses equally on the habits and the medicine.
Yes — it was originally developed for type 2 diabetes management and has an extensive safety record in diabetic patients. Dose adjustments and monitoring of blood sugar-lowering medications may be needed. Your doctor manages this as part of the programme.
A prescription alone is a medicine. Inteledoc’s programme is a clinical framework — metabolic assessment, personalised diet, lifestyle coaching, and ongoing medical monitoring — that makes the medicine both safer and significantly more effective. The outcomes from a supervised programme consistently outperform those from unsupervised medication use.
Yes, and it is often particularly beneficial. PCOD is closely associated with insulin resistance — a condition that semaglutide directly addresses through its GLP-1 mechanism. Many women with PCOD-related weight difficulty see improvements in both weight and hormonal balance through a properly supervised semaglutide programme.
Semaglutide acts on GLP-1 receptors alone. Tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors simultaneously — a dual mechanism that has shown even greater average weight loss in clinical trials. Both are available through Inteledoc’s programme. Your doctor will recommend the most appropriate option based on your clinical profile.
Ready to start your doctor-supervised weight loss journey?
Inteledoc — India's first metabolonomics-based weight loss programme. Online & in-person in Gurugram. Plans from ₹1,500/month.
Book a consultation